Switch to:
Also traded in: Germany, Singapore, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.14
LZAGY's Cash to Debt is ranked lower than
90% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. LZAGY: 0.14 )
Ranked among companies with meaningful Cash to Debt only.
LZAGY' s Cash to Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.15 Max: 0.85
Current: 0.14
0.06
0.85
Equity to Asset 0.34
LZAGY's Equity to Asset is ranked lower than
80% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. LZAGY: 0.34 )
Ranked among companies with meaningful Equity to Asset only.
LZAGY' s Equity to Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.34 Max: 0.5
Current: 0.34
0.3
0.5
Interest Coverage 5.53
LZAGY's Interest Coverage is ranked lower than
76% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 47.71 vs. LZAGY: 5.53 )
Ranked among companies with meaningful Interest Coverage only.
LZAGY' s Interest Coverage Range Over the Past 10 Years
Min: 2.13  Med: 5.18 Max: 7.63
Current: 5.53
2.13
7.63
F-Score: 6
Z-Score: 2.52
M-Score: -2.92
WACC vs ROIC
9.36%
8.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 11.25
LZAGY's Operating margin (%) is ranked higher than
78% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. LZAGY: 11.25 )
Ranked among companies with meaningful Operating margin (%) only.
LZAGY' s Operating margin (%) Range Over the Past 10 Years
Min: 7.06  Med: 11.44 Max: 15.02
Current: 11.25
7.06
15.02
Net-margin (%) 7.28
LZAGY's Net-margin (%) is ranked higher than
74% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.57 vs. LZAGY: 7.28 )
Ranked among companies with meaningful Net-margin (%) only.
LZAGY' s Net-margin (%) Range Over the Past 10 Years
Min: 2.43  Med: 6.90 Max: 14.27
Current: 7.28
2.43
14.27
ROE (%) 13.35
LZAGY's ROE (%) is ranked higher than
81% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.04 vs. LZAGY: 13.35 )
Ranked among companies with meaningful ROE (%) only.
LZAGY' s ROE (%) Range Over the Past 10 Years
Min: 4.11  Med: 11.75 Max: 22.52
Current: 13.35
4.11
22.52
ROA (%) 4.44
LZAGY's ROA (%) is ranked higher than
70% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.95 vs. LZAGY: 4.44 )
Ranked among companies with meaningful ROA (%) only.
LZAGY' s ROA (%) Range Over the Past 10 Years
Min: 1.3  Med: 4.04 Max: 7.45
Current: 4.44
1.3
7.45
ROC (Joel Greenblatt) (%) 19.22
LZAGY's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -13.49 vs. LZAGY: 19.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LZAGY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 7.93  Med: 12.67 Max: 20.68
Current: 19.22
7.93
20.68
Revenue Growth (3Y)(%) -1.50
LZAGY's Revenue Growth (3Y)(%) is ranked lower than
63% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. LZAGY: -1.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LZAGY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -5.5  Med: 7.90 Max: 12.8
Current: -1.5
-5.5
12.8
EBITDA Growth (3Y)(%) 3.30
LZAGY's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.10 vs. LZAGY: 3.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
LZAGY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -12.4  Med: 3.30 Max: 20.9
Current: 3.3
-12.4
20.9
EPS Growth (3Y)(%) 16.20
LZAGY's EPS Growth (3Y)(%) is ranked higher than
77% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.10 vs. LZAGY: 16.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
LZAGY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.9  Med: 1.90 Max: 29.5
Current: 16.2
-32.9
29.5
» LZAGY's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-22)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with LZAGY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 30.89
LZAGY's P/E(ttm) is ranked lower than
51% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.91 vs. LZAGY: 30.89 )
Ranked among companies with meaningful P/E(ttm) only.
LZAGY' s P/E(ttm) Range Over the Past 10 Years
Min: 8.61  Med: 22.42 Max: 69.7
Current: 30.89
8.61
69.7
Forward P/E 18.08
LZAGY's Forward P/E is ranked lower than
52% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.80 vs. LZAGY: 18.08 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 30.89
LZAGY's PE(NRI) is ranked lower than
54% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.15 vs. LZAGY: 30.89 )
Ranked among companies with meaningful PE(NRI) only.
LZAGY' s PE(NRI) Range Over the Past 10 Years
Min: 8.61  Med: 21.64 Max: 69.78
Current: 30.89
8.61
69.78
Price/Owner Earnings (ttm) 21.04
LZAGY's Price/Owner Earnings (ttm) is ranked higher than
68% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.38 vs. LZAGY: 21.04 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
LZAGY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.8  Med: 73.63 Max: 166.57
Current: 21.04
8.8
166.57
P/B 3.99
LZAGY's P/B is ranked lower than
61% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.03 vs. LZAGY: 3.99 )
Ranked among companies with meaningful P/B only.
LZAGY' s P/B Range Over the Past 10 Years
Min: 0.81  Med: 2.11 Max: 4.04
Current: 3.99
0.81
4.04
P/S 2.27
LZAGY's P/S is ranked higher than
63% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.23 vs. LZAGY: 2.27 )
Ranked among companies with meaningful P/S only.
LZAGY' s P/S Range Over the Past 10 Years
Min: 0.63  Med: 1.52 Max: 2.58
Current: 2.27
0.63
2.58
PFCF 17.96
LZAGY's PFCF is ranked higher than
75% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.91 vs. LZAGY: 17.96 )
Ranked among companies with meaningful PFCF only.
LZAGY' s PFCF Range Over the Past 10 Years
Min: 6.17  Med: 19.10 Max: 211.68
Current: 17.96
6.17
211.68
POCF 11.56
LZAGY's POCF is ranked higher than
75% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.86 vs. LZAGY: 11.56 )
Ranked among companies with meaningful POCF only.
LZAGY' s POCF Range Over the Past 10 Years
Min: 3.47  Med: 10.20 Max: 36.19
Current: 11.56
3.47
36.19
EV-to-EBIT 24.13
LZAGY's EV-to-EBIT is ranked lower than
61% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.90 vs. LZAGY: 24.13 )
Ranked among companies with meaningful EV-to-EBIT only.
LZAGY' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.8  Med: 19.60 Max: 32.6
Current: 24.13
9.8
32.6
EV-to-EBITDA 14.15
LZAGY's EV-to-EBITDA is ranked higher than
53% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.72 vs. LZAGY: 14.15 )
Ranked among companies with meaningful EV-to-EBITDA only.
LZAGY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.7  Med: 10.20 Max: 16
Current: 14.15
5.7
16
PEG 11.33
LZAGY's PEG is ranked lower than
94% of the 36 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. LZAGY: 11.33 )
Ranked among companies with meaningful PEG only.
LZAGY' s PEG Range Over the Past 10 Years
Min: 0.57  Med: 3.17 Max: 16.51
Current: 11.33
0.57
16.51
Shiller P/E 33.52
LZAGY's Shiller P/E is ranked higher than
60% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 38.04 vs. LZAGY: 33.52 )
Ranked among companies with meaningful Shiller P/E only.
LZAGY' s Shiller P/E Range Over the Past 10 Years
Min: 19.36  Med: 28.17 Max: 34.11
Current: 33.52
19.36
34.11
Current Ratio 1.17
LZAGY's Current Ratio is ranked lower than
83% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.71 vs. LZAGY: 1.17 )
Ranked among companies with meaningful Current Ratio only.
LZAGY' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 1.30 Max: 1.84
Current: 1.17
0.97
1.84
Quick Ratio 0.60
LZAGY's Quick Ratio is ranked lower than
90% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. LZAGY: 0.60 )
Ranked among companies with meaningful Quick Ratio only.
LZAGY' s Quick Ratio Range Over the Past 10 Years
Min: 0.6  Med: 0.83 Max: 1.09
Current: 0.6
0.6
1.09
Days Inventory 80.59
LZAGY's Days Inventory is ranked higher than
55% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 97.63 vs. LZAGY: 80.59 )
Ranked among companies with meaningful Days Inventory only.
LZAGY' s Days Inventory Range Over the Past 10 Years
Min: 95  Med: 112.30 Max: 123.17
Current: 80.59
95
123.17
Days Sales Outstanding 51.64
LZAGY's Days Sales Outstanding is ranked higher than
61% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.21 vs. LZAGY: 51.64 )
Ranked among companies with meaningful Days Sales Outstanding only.
LZAGY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 51.64  Med: 60.43 Max: 94.23
Current: 51.64
51.64
94.23
Days Payable 39.42
LZAGY's Days Payable is ranked lower than
65% of the 162 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.98 vs. LZAGY: 39.42 )
Ranked among companies with meaningful Days Payable only.
LZAGY' s Days Payable Range Over the Past 10 Years
Min: 29.47  Med: 37.08 Max: 53.87
Current: 39.42
29.47
53.87

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.56
LZAGY's Dividend Yield is ranked higher than
61% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.39 vs. LZAGY: 1.56 )
Ranked among companies with meaningful Dividend Yield only.
LZAGY' s Dividend Yield Range Over the Past 10 Years
Min: 0.96  Med: 2.21 Max: 6.38
Current: 1.56
0.96
6.38
Dividend Payout 0.46
LZAGY's Dividend Payout is ranked lower than
70% of the 47 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.34 vs. LZAGY: 0.46 )
Ranked among companies with meaningful Dividend Payout only.
LZAGY' s Dividend Payout Range Over the Past 10 Years
Min: 0.22  Med: 0.45 Max: 1.29
Current: 0.46
0.22
1.29
Dividend Growth (3y) -100.00
LZAGY's Dividend Growth (3y) is ranked lower than
97% of the 32 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.50 vs. LZAGY: -100.00 )
Ranked among companies with meaningful Dividend Growth (3y) only.
LZAGY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -100  Med: 7.10 Max: 10.4
Current: -100
-100
10.4
Forward Dividend Yield 1.54
LZAGY's Forward Dividend Yield is ranked higher than
59% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.38 vs. LZAGY: 1.54 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.54
LZAGY's Yield on cost (5-Year) is ranked higher than
52% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.67 vs. LZAGY: 1.54 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
LZAGY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.96  Med: 2.21 Max: 6.38
Current: 1.54
0.96
6.38
3-Year Average Share Buyback Ratio -0.50
LZAGY's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.30 vs. LZAGY: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LZAGY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.4  Med: -0.20 Max: 2.2
Current: -0.5
-3.4
2.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 46.44
LZAGY's Price/Tangible Book is ranked lower than
97% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. LZAGY: 46.44 )
Ranked among companies with meaningful Price/Tangible Book only.
LZAGY' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.27  Med: 14.73 Max: 47.44
Current: 46.44
2.27
47.44
Price/Projected FCF 1.89
LZAGY's Price/Projected FCF is ranked higher than
59% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. LZAGY: 1.89 )
Ranked among companies with meaningful Price/Projected FCF only.
LZAGY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.57  Med: 2.11 Max: 2.88
Current: 1.89
1.57
2.88
Price/Median PS Value 1.50
LZAGY's Price/Median PS Value is ranked lower than
80% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. LZAGY: 1.50 )
Ranked among companies with meaningful Price/Median PS Value only.
LZAGY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.43  Med: 0.97 Max: 1.5
Current: 1.5
0.43
1.5
Price/Graham Number 8.04
LZAGY's Price/Graham Number is ranked lower than
90% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. LZAGY: 8.04 )
Ranked among companies with meaningful Price/Graham Number only.
LZAGY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.17  Med: 3.11 Max: 8
Current: 8.04
1.17
8
Earnings Yield (Greenblatt) (%) 4.15
LZAGY's Earnings Yield (Greenblatt) (%) is ranked higher than
70% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.10 vs. LZAGY: 4.15 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LZAGY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.1  Med: 5.10 Max: 10.2
Current: 4.15
3.1
10.2
Forward Rate of Return (Yacktman) (%) 5.83
LZAGY's Forward Rate of Return (Yacktman) (%) is ranked lower than
59% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.85 vs. LZAGY: 5.83 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
LZAGY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5.1  Med: 3.50 Max: 17
Current: 5.83
-5.1
17

More Statistics

Revenue(Mil) $3921
EPS $ 0.54
Beta0.97
Short Percentage of Float0.00%
52-Week Range $12.83 - 17.33
Shares Outstanding(Mil)522.83

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 3,169 3,314
EPS($) 0.63 0.71
EPS without NRI($) 0.63 0.71

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NYSE:TMO, TSE:6869, NYSE:A, NYSE:LH, NYSE:DGX » details
Traded in other countries:LO3.Germany, O6Z.Singapore, LONN.Switzerland, 0QNO.UK,
Lonza Group AG was founded in 1897. The Company is a suppliers of biopharmaceuticals to the Pharma&Biotech and Specialty Ingredient markets. Its products and services range from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens, from the manufacture of vitamin B compounds and organic personal care ingredients to agricultural services and products. The Company operates in two market segments: The Lonza Pharma&Biotech and The Lonza Specialty Ingredients. The Lonza Pharma&Biotech (LPB) market segment clusters all of its offerings for pharmaceutical markets, with strong Lonza positions in Custom Development, Custom Manufacturing and Bioscience Solutions. The Lonza Specialty Ingredients (LSI) market segment includes consumer-oriented offerings, with Consumer Care encompassing its Personal Care & Preservation, Nutrition and Hygiene offerings.
» More Articles for LZAGY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Lonza Reports Record First Quarter Apr 26 2016
Lonza Announces Results of the 2016 Annual General Meeting – Annual General Meeting Accepts All... Apr 22 2016
Blackstone's Exit Opportunity Apr 14 2016
Exclusive: Lonza in bid to acquire Catalent - sources Apr 13 2016
Exclusive: Lonza in bid to acquire Catalent - sources Apr 13 2016
Exclusive: Lonza in bid to acquire Catalent - sources Apr 13 2016
Catalent Rises on Report Lonza Group Offered to Buy It Apr 13 2016
Dr. Christoph Kolano Joins Lonza Consumer Care as Associate Director Global Portfolio Development Apr 12 2016
Lonza Polyaldo ® 10-1-CC Polyglyceryl Ester Provides High-Performing and Mild, Foam Boost for... Apr 12 2016
New Catalog from Lonza Highlights Functionalities for Easy Personal Care Solution Identification Apr 11 2016
Lonza Consumer Care to Conduct Innovation Seminar and Formulation Lab on Polyglyceryl Technology at... Apr 11 2016
Lonza to Highlight a New 3D Culture System Reforming Spheroid Culture and Analysis at AACR 2016 Apr 06 2016
Lonza Adds a New Innovative In-Can Preservative to the Proxel ® Range Apr 05 2016
Technavio Announces Top Six Vendors in the Global Specialty Biocides Market from 2016 to 2020 Apr 04 2016
Lonza Launches Sentinel APART™ Server-Based Platform Designed to Help Improve the Quality and... Mar 30 2016
Lonza to Host Free Webinar: Medical Devices: Guidelines for Performing the Bacterial Endotoxins Test... Mar 30 2016
Lonza Consumer Care Announces Appointment of Dr. Russell Elliott PhD as Director of Skin Care... Mar 23 2016
Lonza Publishes Annual Report 2015 and Invitation to the 2016 Annual General Meeting Mar 22 2016
Lonza Group AG Earnings Analysis: 2015 By the Numbers Feb 02 2016
Lonza Reports Strong Sales and Profit Growth in 2015 Jan 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK